HIV/AIDS Clinical Care for April 30, 2012
SUMMARY AND COMMENT
April 30, 2012 | Rochelle P. Walensky, MD, MPH
PrEP may be cost-effective, particularly in high-risk MSM, but many questions remain.
Reviewing: Juusola JL et al. Ann Intern Med 2012 Apr 17; 156:541
SUMMARY AND COMMENT
Patients who switched to tenofovir from AZT experienced significant decreases in BMD. Those who switched to abacavir did not.
Reviewing: Rasmussen TA et al. PLoS ONE 2012 Mar 29; 7:e32445
SUMMARY AND COMMENT
In Australia, they did well in some things, poorly in others.
Reviewing: Bloch M et al. J Acquir Immune Defic Syndr 2012 Apr 15; 59:478
FEATURE
April 30, 2012
|
No hay comentarios:
Publicar un comentario